Growing body of clinical evidence supports use of Company’s FDA-Cleared BNA™ platform to provide objective measures of drug efficacy and ...

Firefly Neuroscience (AIFF) highlights two impactful studies that demonstrate the utility of advanced Resting Electroencephalograms and ...

Firefly Neuroscience, Inc. (NASDAQ:AIFF – Get Free Report) traded down 3.9% during mid-day trading on Tuesday . The stock traded as low as $3.43 and last traded at $3.70. 523,068 shares changed hands ...

Firefly Neuroscience, Inc. is an artificial intelligence (AI) technology company, which engages in developing neuroscientific solutions for mental illnesses and neurological disorders. It offers ...

Firefly Neuroscience shares are trading higher on Tuesday after the company announced the advancement of research to assess a patient's brain age.

Firefly Neuroscience shares doubled to $3.90 Tuesday after the company said it is advancing its research used to assess a patient's brain age--an estimation of the biological age of a person's ...

(RTTNews) - Firefly Neuroscience (AIFF), an AI company focused on improving brain health outcomes, announced on Tuesday, a major research breakthrough in estimating the biological age of the brain ...

Measuring brain age with EEG and BNA™ could lead to a proactive and scalable approach to early screening for Alzheimer's patients KENMORE, N.Y., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Firefly Neuroscience, ...

TORONTO, Dec. 31, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly,” “we,” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence ...

Growing body of clinical evidence supports use of Company’s FDA-Cleared BNA™ platform to provide objective measures of drug efficacy and cognitive change, driving innovation in brain health ...

Firefly Neuroscience, Inc., a medical technology and artificial intelligence company, provides neuroscientific solutions that improve outcomes for patients with mental illnesses and neurological ...